Trial Profile
Phase 1b study of U3-1287 in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Patritumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 25 May 2016 New trial record